Wave Life Sciences Ltd [WVE] stock is trading at $10.22, down -0.49%. An important factor to consider is whether the stock is rising or falling in short-term value. The WVE shares have gain 8.72% over the last week, with a monthly amount drifted -6.32%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Wave Life Sciences Ltd [NASDAQ: WVE] stock has seen the most recent analyst activity on February 25, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $26. Previously, Raymond James upgraded its rating to Strong Buy on October 16, 2024, and kept the price target unchanged to $22. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $11 on September 19, 2024. JP Morgan initiated its recommendation with a Overweight and recommended $10 as its price target on September 09, 2024. Wells Fargo started tracking with a Overweight rating for this stock on May 15, 2024, and assigned it a price target of $11. In a note dated December 19, 2023, Leerink Partners upgraded an Outperform rating on this stock and boosted its target price from $5 to $12.
Wave Life Sciences Ltd [WVE] stock has fluctuated between $4.25 and $16.74 over the past year. Currently, Wall Street analysts expect the stock to reach $22.14 within the next 12 months. Wave Life Sciences Ltd [NASDAQ: WVE] shares were valued at $10.22 at the most recent close of the market. An investor can expect a potential return of 116.63% based on the average WVE price forecast.
Analyzing the WVE fundamentals
Wave Life Sciences Ltd [NASDAQ:WVE] reported sales of 108.30M for the trailing twelve months, which represents a growth of 188.23%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -1.02%, Pretax Profit Margin comes in at -0.9%, and Net Profit Margin reading is -0.9%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.0 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.97 points at the first support level, and at 9.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.55, and for the 2nd resistance point, it is at 10.87.
Ratios To Look Out For
For context, Wave Life Sciences Ltd’s Current Ratio is 2.89. On the other hand, the Quick Ratio is 2.89, and the Cash Ratio is 2.72. Considering the valuation of this stock, the price to sales ratio is 14.48, the price to book ratio is 7.47.
Transactions by insiders
Recent insider trading involved BOLNO PAUL, President and CEO, that happened on Mar 07 ’25 when 0.17 million shares were sold. Officer, PAUL BOLNO completed a deal on Mar 07 ’25 to buy 0.17 million shares. Meanwhile, President and CEO BOLNO PAUL sold 50000.0 shares on Nov 25 ’24.
